New ACC Guidance on Obesity and Cardiovascular Disease: What Every NP Needs to Know

---

If you're a nurse practitioner in primary care, family practice, or cardiology, you already know that the obesity conversation has fundamentally changed. We're no longer in the era of "eat less, move more" as the sole clinical recommendation. The American College of Cardiology dropped two major guidance documents in August 2025 that every NP managing cardiovascular risk needs to have on their radar — and if you missed them, consider this your clinical catch-up.

Let's break down what matters for your practice.

---

Two Documents, One Clear Message

The ACC released a Concise Clinical Guidance (CCG) on the medical management of obesity and a Scientific Statement focused specifically on treating obesity in adults with heart failure. Both documents signal a seismic shift in how we should be thinking about weight management as a core component of cardiovascular care — not a side conversation.

The CCG was led by Olivia Gilbert, MD, MSc, FACC, and Martha Gulati, MD, MS, FACC. The Scientific Statement on heart failure and obesity was led by Michelle M. Kittleson, MD, PhD, FACC.

---

The Big Takeaway: Obesity Is Multifactorial — Treat It That Way

The CCG lays out what many of us have observed clinically but haven't always had guideline-level backing to support: the causes of obesity are multiple. We're talking genetics, neurological and psychological factors, nutrient and hormonal imbalances, environmental influences, social determinants of health, and even medical conditions and medications themselves.

For NPs, this is validation. When your patient tells you they've "tried everything," the science now formally acknowledges that willpower isn't the issue. The pathophysiology is complex, and our treatment approach needs to reflect that complexity.

---

Pharmacotherapy: No More "Try and Fail"

Here's the line every NP should commit to memory from this guidance: patients should not be required to "try and fail" lifestyle changes before initiating pharmacotherapy. That said, lifestyle interventions should always be offered alongside obesity medications — not as a prerequisite, but as a complement.

This is a critical distinction for our practice. How many times have we felt pressure (from insurance companies, from institutional culture, from our own training) to exhaust lifestyle modifications before considering medication? This guidance explicitly says that's not the standard anymore.

What's Working: The Pharmacologic Landscape

Among FDA-approved medications, the guidance highlights two agents with the strongest efficacy data:

• Semaglutide (GLP-1 receptor agonist)
• Tirzepatide (GLP-1/GIP receptor agonist)

Clinical trial data and real-world observational evidence suggest slightly greater weight loss with tirzepatide. However — and this is the reality check for primary care NPs — insurance coverage, availability, and affordability are likely to dictate agent selection more than head-to-head efficacy data.

Sound familiar? Welcome to every prior authorization conversation you've ever had.

---

The Cardiovascular Connection: Why This Matters Beyond the Scale

The guidance makes the cardiovascular argument crystal clear. Obesity-related CV disease risks include:

• Sleep apnea
• Dyslipidemia
• Chronic inflammation
• Hypertension
• Type 2 diabetes and insulin resistance
• Atrial fibrillation
• Heart failure (both HFpEF and HFrEF)
• ASCVD
• VTE/PE
• Valvular heart disease
• Sudden cardiac death

The document notes that unhealthy weight has been linked to more than 60 conditions. And the cardiovascular risk reduction data is compelling — clinical evidence supports these medications leading to a reduction in major adverse cardiovascular events (MACE), including cardiovascular death, MI, and stroke, particularly in individuals with type 2 diabetes and elevated CV risk.

For NPs managing patients with multiple comorbidities, this reframes the conversation. Weight management isn't cosmetic. It's cardiovascular risk reduction.

---

Obesity in Heart Failure: A New Frontier

The Scientific Statement specifically addresses obesity management in adults with heart failure, with particular focus on Stage 2 HFpEF. This is the first in a new series of clinical guidance from the ACC targeting areas where evidence is evolving.

Here's what the central illustration from the statement tells us about weight loss strategies in HF:

Behavioral Changes (Diet and Exercise)

• 5%–10% weight loss achievable
• Exercise and caloric restriction have additive effects
• Weight loss is difficult to sustain long-term with significant regain
• Limited data specifically in HF, but successful weight loss is associated with improved functional status and reduced symptom burden in HFpEF

Anti-Obesity Medications

• 10%–20% weight loss achievable
• Weight regain occurs with cessation of medications
• Semaglutide: Significant improvement in functional status and symptom burden in HFpEF; reduced rates of MACE and HF hospitalization
• Tirzepatide: Additional benefit of reduced risk for CV death or HF events in HFpEF (though low event rates limit conclusive assessment)

Metabolic and Bariatric Surgery

• 10%–30% weight loss, often sustained over years
• No randomized data specifically in HF populations
• Observational data suggests reduced risk of incident HF and decreased rates of HF hospitalization and inpatient mortality
• Important caveat: individuals with HF, especially HFrEF, may have higher rates of complications with surgery

---

Six Key Clinical Decision-Making Areas for NPs

The CCG outlines six areas that should shape your clinical approach:

1. Rationale and Eligibility Pharmacotherapy balances effectiveness and invasiveness. Eligibility may be determined by BMI thresholds or other risk indicators. These therapies can be adjusted to minimize adverse effects and personalize care.

2. Pharmacological Options Know your agents, know the data, and know the insurance landscape. Semaglutide and tirzepatide lead in efficacy, but practical access drives real-world prescribing decisions.

3. Impact on Cardiovascular Risk The MACE reduction data is the strongest argument you have when justifying treatment to insurers, patients, and colleagues.

4. Multidisciplinary Care Approaches Team-based care is emphasized — assess modifiable risk factors, identify comorbidities, and tailor strategies. NPs are perfectly positioned to quarterback this.

5. Reducing Bias and Improving Patient Experience Use person-first language. Create welcoming clinical environments. Address weight stigma directly. Validate the lifelong journey patients experience with this chronic disease. This isn't a soft recommendation — it's guideline-level.

6. Access Considerations Insurance coverage remains the single biggest barrier. Strategies include identifying patients most likely to benefit, closely monitoring treatment outcomes, and price negotiations.

---

What This Means for Your NP Practice

Here's my bottom line for fellow NPs:

Start the conversation. If you're managing a patient's hypertension, diabetes, dyslipidemia, or heart failure, and they have obesity — you now have ACC-level guidance supporting pharmacologic intervention as part of their cardiovascular treatment plan. Not instead of lifestyle changes. Alongside them.

Document the cardiovascular indication. When you're writing that prior authorization, frame it as cardiovascular risk reduction. The MACE data is your best friend.

Don't wait for cardiology to initiate. As the CCG states, weight management by the cardiovascular community — and I'd argue the primary care community even more so — needs to be embraced. NPs in primary care are often the first and most consistent point of contact. We are the cardiovascular community.

Stay current on access pathways. The insurance landscape for GLP-1 receptor agonists and GIP/GLP-1 receptor agonists is evolving rapidly. Know your formularies, know your PA requirements, and know the manufacturer assistance programs.

---

Clinical Pearl

When documenting obesity in your patients' charts, code it as the chronic disease it is. Use the cardiovascular risk language from this guidance. Your documentation should reflect that you're treating obesity not as a lifestyle choice, but as a multifactorial chronic disease with direct cardiovascular consequences. This matters for your patients' care continuity, insurance approvals, and outcomes tracking.

---

Resources

• ACC Concise Clinical Guidance on Medical Weight Management — published in JACC, August 2025
• ACC Scientific Statement: Obesity in Adults with Heart Failure — published in JACC, August 2025
• CardioSmart.org/Weight — patient education infographics and materials

---

What changes are you seeing in your practice around obesity management? Are your patients getting access to these medications? Drop a comment below — I'd love to hear from NPs in the trenches.

---

Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC NP 

 

Psychiatry & Mental Health

Choosing the Right Antidepressant Just Got a Little Easier: What NPs Need to Know About the PETRUSHKA Trial

A new decision-support tool helped patients stay on their antidepressant longer and feel better at six months. Here's what it means for your prescribing practice.

If you've ever stared at a list of SSRIs and SNRIs wondering which one will actually work for the patient sitting across from you, you're not alone. The antidepressant selection process has long been described as "educated trial and error," and for good reason—we've had limited tools to meaningfully guide that first-line choice. A large new randomized trial published in JAMA in March 2026 offers some encouraging evidence that a structured, personalized approach can improve outcomes.

The Study at a Glance

Cipriani and colleagues conducted a multicenter RCT across 47 sites in Brazil, Canada, and the UK, enrolling 540 adults aged 18–74 with major depressive disorder. Participants were randomized 1:1 to either a clinical decision-support system called the PETRUSHKA tool or usual care. The tool is web-based and uses a combination of clinical and demographic predictors alongside patient preferences to recommend a specific antidepressant.

The primary outcome was straightforward and clinically relevant: treatment discontinuation due to any cause at 8 weeks. Secondary outcomes included discontinuation due to adverse events, plus changes in depressive symptoms (PHQ-9) and anxiety symptoms (GAD-7) at 24 weeks.

17%

PETRUSHKA Group

Discontinued at 8 wks

27%

Usual Care

Discontinued at 8 wks

0.62

Adjusted RR

95% CI: 0.44–0.88

That's a 38% relative risk reduction in all-cause discontinuation—a clinically meaningful difference. When the researchers looked specifically at discontinuation due to adverse events, the PETRUSHKA group also came out ahead: 9% versus 16% (adjusted RR 0.59, p = .04). This suggests the tool was helping match patients to medications they could actually tolerate.

The Longer View: 24-Week Outcomes

At 24 weeks, participants in the PETRUSHKA group had lower PHQ-9 scores (mean 7.1 vs 9.2, adjusted difference −1.92 points, p < .001) and lower GAD-7 scores (mean 4.6 vs 5.8, adjusted difference −1.39 points, p = .002). A roughly 2-point difference on the PHQ-9 might not sound dramatic, but in a population where the baseline mean was 16.6, a drop to 7.1 puts the average PETRUSHKA patient near the remission threshold of 5, while the usual care group averaged closer to mild-moderate symptom persistence.

Clinical context: A PHQ-9 score of 5–9 corresponds to mild depressive symptoms. Moving a patient from 9.2 to 7.1 represents a meaningful shift in day-to-day functioning—better sleep, more energy, improved concentration, and greater engagement with life.

What Does the Tool Actually Do?

PETRUSHKA integrates clinical variables (symptom profile, comorbidities, prior treatment history) and demographic factors with patient preferences—for example, whether a patient is more concerned about weight gain, sexual side effects, or sedation. The tool then generates a personalized antidepressant recommendation based on the available evidence from network meta-analyses and individual patient data.

This is not pharmacogenomic testing, which remains controversial in psychiatry and is not yet recommended as standard practice by most guidelines. Instead, PETRUSHKA works with the clinical information you're already gathering in a thorough intake. Think of it as a structured framework that synthesizes evidence in a way that's hard to do reliably in your head during a 20-minute visit.

Limitations Worth Noting

The authors themselves flag two significant concerns. First, this was not a double-blind trial—clinicians and patients knew which group they were in, which could have introduced expectation effects. If a patient knows their antidepressant was "personalized" for them, that may increase adherence through a placebo-adjacent mechanism. That's not necessarily a bad thing in real-world practice (whatever keeps patients on effective treatment is welcome), but it tempers the strength of the efficacy signal.

Second, there was a substantial amount of missing data, particularly at the 24-week follow-up, where only 129 participants per group were available for analysis out of the original 493. When nearly half your sample is missing at a key time point, the results need to be interpreted cautiously.

Why This Matters for NP Practice

Nurse practitioners prescribe a large and growing share of antidepressants in the United States, particularly in primary care and psychiatric-mental health settings. Many of us work in environments where we don't have the luxury of a consulting psychiatrist down the hall, and our patients are often dealing with comorbid anxiety, chronic pain, insomnia, and other factors that make antidepressant selection genuinely complex.

The PETRUSHKA trial doesn't solve the antidepressant selection puzzle entirely, but it validates an important principle: structured decision-making that integrates both evidence and patient preferences can outperform clinical intuition alone. That's not a knock on clinical experience—it's a recognition that the sheer volume of evidence across dozens of antidepressants and hundreds of patient variables exceeds what any individual clinician can synthesize in real time.

Bottom Line for NPs

1. The core finding is about adherence, not just efficacy. Patients who received a personalized recommendation were significantly more likely to still be taking their medication at 8 weeks. In a condition where premature discontinuation is one of the biggest barriers to successful treatment, this matters enormously.

2. Patient preferences are part of the equation. The tool explicitly incorporates what side effects patients are most concerned about. This aligns with the shared decision-making model that NPs are already trained to use—the study just provides a structured framework to make those conversations more systematic.

3. Watch this space. The PETRUSHKA tool isn't widely available yet, but the broader movement toward clinical decision-support systems in mental health is accelerating. Familiarize yourself with the concept, and look for future studies that replicate these findings with double-blind designs and better retention.

4. Your clinical judgment still matters. Decision-support tools augment your expertise; they don't replace it. You still know your patient's full story, their social context, their insurance formulary, and the nuances that no algorithm captures.

Reference

Cipriani A, Fernandes KBP, Mulsant BH, et al. A decision-support system to personalize antidepressant treatment in major depressive disorder: a randomized clinical trial. JAMA. Published online March 4, 2026. doi:10.1001/jama.2026.1327

AntidepressantsMajor Depressive DisorderClinical Decision SupportEvidence-Based PracticeMental HealthNP PrescribingShared Decision-Making

Disclosure: This post is for educational purposes only and does not constitute medical advice. The author has no financial relationship with the developers of the PETRUSHKA tool. As always, clinical decisions should be based on the full context of each individual patient encounter.

Delivering a Down Syndrome Diagnosis with Confidence and Compassion: AAP Guidelines Meet the SPIKES Strategy

 

Delivering a Down Syndrome Diagnosis with Confidence and Compassion: AAP Guidelines Meet the SPIKES Strategy

---

If you've ever had to deliver difficult news to a patient or family — and let's be honest, most of us have — you know the weight of those moments. The clinical knowledge matters, but how you communicate can shape a family's trajectory for years to come. A powerful session at the NAPNAP 2026 National Conference in Pittsburgh brought this truth into sharp focus, pairing the updated AAP health supervision guidelines for Down syndrome with a structured communication framework called SPIKES.

The session was co-presented by Kristina Banks, DNP, MSN, APRN, CPNP-PC, Specialty Director of Pediatric Nurse Practitioner programs at Case Western University, and Katharine Roanleigh, MSN, APRN, FNP-BC, CPNP-PC — a fellow NP who received a prenatal Down syndrome diagnosis for her own son in December 2023. Together, they modeled what evidence-based care looks like when it's grounded in both science and lived experience.

This post walks through the key clinical takeaways and explores how the SPIKES framework can help NPs navigate these conversations with both competence and heart.

Why This Matters for Every NP

Down syndrome is the most common chromosomal abnormality that clinicians across every setting will encounter. As Dr. Banks emphasized during her presentation, life expectancy for individuals with Down syndrome has improved dramatically — but only because clinicians are applying the evidence-based screening and intervention protocols that make early identification and management possible.

Whether you're in primary care, family practice, urgent care, or pediatrics, you will care for patients with Down syndrome or their families. Being prepared isn't optional.

The SPIKES Framework: Turning Hard Conversations into Trust

Before diving into the clinical guidelines, let's talk about the communication piece — because this is where so many of us were never formally trained.

SPIKES is a six-step protocol originally developed for delivering bad news in oncology, but it translates beautifully to pediatric and prenatal settings. Here's how it breaks down:

S — Setting: Prepare the physical environment. Find a quiet, private space. Minimize interruptions. These details communicate respect before you say a single word.

P — Perception: Ask the family what they already know or suspect. This step prevents you from making assumptions and gives you a starting point for the conversation.

I — Invitation: Ask how the family would like to receive the information. Some families want the big picture first; others want every detail. Letting them choose gives them agency during a moment when they may feel powerless.

K — Knowledge: Deliver the medical information using simple, clear language. Break it into small, digestible chunks rather than overwhelming the family with everything at once.

E — Empathy: Acknowledge the emotional weight. Sit with the family in that moment. You don't need to fix the feelings — you need to validate them.

S — Strategy: Collaborate on next steps. This is where you shift from delivering news to building a plan together — referrals, support resources, follow-up care, and what to expect.

Dr. Banks outlined four core objectives of the SPIKES approach: gathering information from the family, transmitting necessary medical information, providing emotional support, and collaborating with the family on a treatment strategy. Notice the emphasis on collaboration — this isn't a one-directional information dump.

The AAP Health Supervision Guidelines by Age

The 2022 AAP guidelines provide age-stratified recommendations for managing Down syndrome across the lifespan. Here's a summary of the key milestones every NP should know.

Prenatal Period

The AAP recommends cell-free DNA (cfDNA) screening as early as 9–10 weeks' gestation to identify Down syndrome, along with a "Quad Screen" in the first or second trimester. Once a prenatal diagnosis is made, conversations about additional screening, specialist referrals, and delivery planning should begin immediately.

Ms. Roanleigh's experience illustrates why close surveillance matters: she underwent confirmatory amniocentesis at 18 weeks, regular anatomy scans, and at 35 weeks was referred for emergent fetal echocardiography after an enlarged fetal liver and spleen were identified — ultimately leading to labor induction.

Birth to 1 Month

In the immediate postnatal period, the focus is on comprehensive evaluation for comorbidities. Key areas for assessment include feeding difficulties, constipation, GERD, wheezing or noisy breathing, congenital heart defects, hypotonia, cataracts, congenital hearing loss, hematologic abnormalities, and congenital hypothyroidism.

An important clinical pearl from the session: congratulate the family first, and refer to the baby by name. This simple act of humanity sets the tone for the entire care relationship.

Anticipatory guidance should cover support resources, cervical spine positioning, susceptibility to respiratory infections and appropriate prophylaxis, and the appropriateness of complementary therapies.

Ms. Roanleigh's son Kiegan was born with transient abnormal myelopoiesis (TAM), a preleukemia condition seen in Down syndrome, and began chemotherapy on day two of life. He responded well and was discharged from the NICU at two months.

1 Month to 1 Year

During the first year, the AAP recommends using Down syndrome-specific CDC growth charts, ongoing feeding assessment, an ophthalmology exam within the first six months, and regular thyroid, cardiac, hearing, and dermatology screenings along with age-appropriate vaccinations.

Equally important — and often overlooked — is assessing the emotional status of the caregivers and the family unit. This is a period of intense medical activity for families, and burnout is real. As Ms. Roanleigh described, Kiegan's first year involved monthly lab work and appointments across nephrology, urology, ophthalmology, endocrinology, ENT, audiology, hepatology, pulmonary hypertension, feeding, and Down syndrome clinics, plus speech, physical, and occupational therapy and multiple surgeries.

1 to 5 Years

In the toddler through early childhood years, ongoing surveillance includes growth monitoring, feeding and respiratory assessment, hearing and vision screening, behavioral and social development evaluation, and neurological monitoring.

Two specific points to remember:

• Atlantoaxial instability becomes relevant as children become more mobile. Families need to know that trampolines must be avoided due to increased spinal cord injury risk.
• A universal sleep study is recommended at 3–4 years of age for all children with Down syndrome.

This is also the time to begin discussing body safety using appropriate anatomic terms, as children with Down syndrome are at higher risk for sexual exploitation.

5 to 12 Years

The school-age period shifts emphasis toward obesity prevention while continuing individualized monitoring of feeding, ophthalmology, thyroid function, cardiology, and neurology.

Clinicians should be aware that some children with Down syndrome experience acute regression during this period — a backsliding in developmental areas that requires prompt evaluation. Girls with Down syndrome may also reach menses earlier than expected, making fertility and gynecologic care relevant discussions even at this stage.

12 Years Through Transition to Adult Care

The adolescent and transition period focuses on fostering independence, supporting sexual development, planning for work transitions, and discussing adult morbidities including premature aging and Alzheimer disease.

Dr. Banks closed with a call to action that resonated deeply: ask individuals with Down syndrome how they want to be advocated for. And advocate beyond the exam room — for policies that sustain Medicaid, school-based interventions, and Individualized Education Programs that support the fullest possible lives.

Common Comorbidities: Know Your Numbers

When coordinating care, keep these prevalence figures in mind for individuals with Down syndrome:

• Hearing problems: ~75%
• Vision problems: 60–80%
• Dermatologic conditions: ~56%
• Otitis media with effusion: 50–70%
• Thyroid disease: ~50%
• Congenital heart disease: 40–50%
• Feeding difficulties: 31–80%
• Respiratory infections: 20–36%
• Hypodontia/delayed dental eruption: ~23%
• Antithyroid antibody positivity: 13–39%

These aren't rare comorbidities — they're expected ones. Proactive screening is the standard of care.

Resources for Families

The NAPNAP session endorsed several resources that NPs can share with families navigating a Down syndrome diagnosis:

• Lettercase — balanced, medically accurate information for new and expectant parents
• Down Syndrome Diagnosis Network — peer support and connection
• Got Transition — tools for managing the healthcare transition from pediatric to adult care

The Bottom Line for NPs

The clinical guidelines give us the roadmap. The SPIKES framework gives us the language. Together, they equip us to provide care that is both scientifically rigorous and deeply human.

Whether you're the NP delivering a prenatal diagnosis, managing a toddler's complex multi-specialty care, or helping an adolescent transition to adult services, your approach matters. Families remember how you made them feel during the hardest moments. Let's make sure they remember compassion, competence, and partnership.

---

Have you used the SPIKES framework or a similar communication model in your practice? I'd love to hear how you approach these conversations — drop a comment below or reach out through the NP Chronicles community.

---

Reference: Banks K, Roanleigh K. Integrating a PNP parent's perspectives with Down syndrome best practices. Presented at: NAPNAP National Conference on Pediatric Health Care; March 18–21, 2026; Pittsburgh, PA.

Source Article: Nye J, Blumenfeld M. Navigating AAP Down Syndrome Guidelines and the SPIKES Strategy for Pediatric NPs. Clinical Advisor. March 30, 2026.

 

Clinical Updates · Cardiology

The 2026 ACC/AHA Dyslipidemia Guidelines:
Everything Primary Care NPs Need to Know Right Now

A comprehensive clinical breakdown of the most significant cholesterol guideline update in nearly a decade.

PublishedApril 2026· NP Chronicles ·12-minute read· Updated from the 2018 ACC/AHA Guideline

The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia dropped this spring — and if you manage patients with cardiovascular risk in primary care, this one is going to change your practice. Here's what you need to know, translated for the clinic floor.

Whether you're seeing a 45-year-old with a new diabetes diagnosis, a 58-year-old post-MI patient not at LDL goal, or a young woman with a family history of premature heart disease, the 2026 guidelines give us clearer targets, updated risk tools, and several entirely new recommendations that simply didn't exist before. Let's break it down.

📋 Quick Context

This guideline is co-authored by 11 major professional organizations and replaces the 2018 ACC/AHA Cholesterol Guideline. It was approved in October–December 2025 and published in the Journal of the American College of Cardiology and Circulation. The evidence review covers literature through April 2025.

01 — Risk AssessmentThe PREVENT Equations Replace the Pooled Cohort Equations

This is the first and most operationally significant change you'll encounter. The old Pooled Cohort Equations (PCE) are out. The new PREVENT-ASCVD equations are now the standard for estimating 10-year cardiovascular risk in adults aged 30–79 without established ASCVD or subclinical atherosclerosis, with LDL-C between 70 and 189 mg/dL.

The PREVENT model is more contemporary, more inclusive, and incorporates additional cardiometabolic factors. Risk is now categorized into four tiers:

<3%Low Risk

3–<5%Borderline Risk

5–<10%Intermediate Risk

≥10%High Risk

The guideline introduces a helpful framework called the "CPR" Model for primary prevention decision-making:

• Calculate 10-year ASCVD risk using PREVENT-ASCVD equations
• Personalize estimated risk by considering factors not included in the equations (risk enhancers, reproductive history, social determinants)
• Reclassify with selective use of CAC scoring and reassess treatment recommendations

🩺 NP Clinical Pearl

The PREVENT calculator is available free at tools.acc.org. Make it a habit to update this with every patient over 30 at their annual wellness visit. The new model also incorporates 30-year risk for patients aged 30–59, which is a meaningful addition for young patients who may feel "too young" to worry about cholesterol.

02 — Lab TestingNew Guidance on What to Measure (and Why It Matters)

Lp(a) — Now Recommended for Everyone, Once

This is a landmark change. For the first time, the guidelines give a Class I (COR 1) recommendation that all adults have lipoprotein(a) [Lp(a)] measured at least once in their lifetime for ASCVD risk assessment. Previously, this was reserved for select high-risk individuals.

⚠️ Why This Matters

Lp(a) ≥125 nmol/L (≥50 mg/dL) confers approximately 1.4× increased ASCVD risk. Levels ≥250 nmol/L (≥100 mg/dL) are associated with a ≥2-fold higher risk. Elevated Lp(a) should prompt more intensified LDL-C lowering and rigorous management of all other modifiable risk factors. Lp(a)-specific therapies are in trials — knowing your patient's level now matters.

ApoB — New Supporting Role in Monitoring

A new COR 2a recommendation supports measuring apolipoprotein B (apoB) in adults on lipid-lowering therapy — particularly those with ASCVD, cardiovascular-kidney-metabolic (CKM) syndrome, type 2 diabetes, and/or elevated triglycerides — once LDL-C and non-HDL-C goals are achieved. ApoB helps identify residual lipoprotein-related risk that a standard lipid panel may underestimate, especially in patients with elevated TG or low achieved LDL-C (<70 mg/dL).

Better LDL-C Calculation

The old Friedewald equation for calculating LDL-C is no longer preferred. The guidelines now recommend either the Martin/Hopkins equation or the Sampson/NIH equation as standard — both are significantly more accurate, especially at low LDL-C levels. Most modern lab systems and electronic health records have already transitioned to these methods, but verify with your lab.

03 — Primary PreventionTreat Earlier, Treat Smarter, Set Goals

The 2026 guidelines make a major philosophical shift: LDL-C and non-HDL-C treatment goals are back. The 2018 guideline moved away from specific targets toward percentage reductions. The 2026 guideline brings both — percentage reductions and specific numeric goals — depending on risk category.

Risk Category	Statin Intensity	LDL-C Goal	Non-HDL-C Goal
Low (<3%), LDL-C <160	Lifestyle counseling only	—	—
Low (<3%), LDL-C 160–189 or 30-yr risk ≥10%	Moderate-intensity (COR 2a)	<100 mg/dL	<130 mg/dL
Borderline (3–<5%)	Moderate-intensity if initiated (COR 2a)	<100 mg/dL	<130 mg/dL
Intermediate (5–<10%)	At least moderate; high if upper range (COR 1)	<100 mg/dL	<130 mg/dL
High (≥10%)	High-intensity (COR 1)	<70 mg/dL	<100 mg/dL

💡 Key Shift for NPs

Borderline-risk patients (3–<5%) can now be treated — this is an upgrade from COR 2b (may be considered) to COR 2a (is reasonable). For intermediate-risk patients, statin initiation is a Class I recommendation. And for the first time, specific LDL-C target goals accompany statin intensity recommendations at every risk tier.

Reproductive Risk Markers Are Now Part of Risk Assessment

New for 2026: a COR 2a recommendation supports considering reproductive risk markers — including early menopause (<45 years), gestational hypertension, preeclampsia, gestational diabetes, and preterm delivery — when personalizing ASCVD risk assessment for primary prevention. These adverse pregnancy outcomes are now recognized as independent cardiovascular risk enhancers that should prompt earlier consideration of lipid-lowering therapy.

04 — CAC ScoringCoronary Artery Calcium Gets Expanded, Actionable Guidance

Coronary artery calcium (CAC) scoring receives its most detailed and actionable guidance to date. It's no longer just a tiebreaker when statin use is uncertain — it now generates its own treatment targets based on score severity.

CAC Score	Recommendation	LDL-C Goal
0 AU	Defer therapy; reassess in 3–7 years (COR 2a, if no high-risk conditions)	—
1–99 AU, <75th percentile	Moderate-intensity statin (COR 2a)	<100 mg/dL
≥100 AU or ≥75th percentile	Initiate LLT (COR 1)	<70 mg/dL
≥300–999 AU	High-intensity statin; intensify to <55 mg/dL if needed (COR 1/2a)	<70 → <55 mg/dL
≥1000 AU	Treat as very high risk (COR 1)	<55 mg/dL

Importantly, incidental CAC found on non-cardiac CT scans (pulmonary emboli workups, chest CTs, etc.) should now be factored into treatment decisions. AI-based algorithms are specifically mentioned as valid tools for detecting coronary atherosclerosis on noncardiac imaging — a forward-thinking addition that reflects real-world practice.

05 — Secondary PreventionLower Goals, More Tools

The 2026 guidelines take a notably more aggressive approach to secondary prevention. Most patients with established ASCVD should now be treated to an LDL-C goal of <55 mg/dL — a target that will require nonstatin therapy in many patients.

🔴 High Risk vs. Very High Risk

The 2026 guideline distinguishes between ASCVD patients who are "not at very high risk" (LDL goal <70 mg/dL and non-HDL <100 mg/dL) and those "at very high risk" (recent ACS, multiple ASCVD events, ASCVD + diabetes/CKD/HeFH — LDL goal <55 mg/dL and non-HDL <85 mg/dL). In practice, most of your established ASCVD patients will qualify for the <55 mg/dL target.

The Nonstatin Toolkit — Now with More Options

When maximally tolerated statin therapy isn't getting patients to goal, the guideline now explicitly supports a stepwise approach using:

Agent	Mechanism	Use Case / Strength
Ezetimibe	NPC1L1 inhibitor	First add-on; oral, well-tolerated (COR 1/2a)
PCSK9 mAbs (evolocumab, alirocumab)	PCSK9 inhibition	Robust LDL lowering 50–60%; injectable q2-4wk (COR 2a)
Bempedoic acid	ATP-citrate lyase inhibitor	Oral option for statin-intolerant patients; new expanded role (COR 2a)
Inclisiran	siRNA targeting PCSK9	New — twice-yearly injection; option for those unable to tolerate PCSK9 mAbs or preferring infrequent dosing (COR 2a)

Inclisiran is the newest addition to the guideline-endorsed toolkit. For patients who struggle with injection frequency or who cannot access or tolerate evolocumab/alirocumab, inclisiran's twice-yearly dosing offers a compelling alternative.

06 — Special PopulationsDiabetes, FH, CKD, HIV, and Cancer Survivors

Diabetes (Ages 40–75)

The foundational recommendation is unchanged — moderate-intensity statin therapy is COR 1 for all adults 40–75 with diabetes without established ASCVD. What's new: explicit LDL-C and non-HDL-C goals are now attached. The target is LDL-C <100 mg/dL and non-HDL-C <130 mg/dL. For those with multiple ASCVD risk factors, high-intensity statin therapy targeting LDL-C <70 mg/dL and non-HDL-C <100 mg/dL is COR 2a.

Familial Hypercholesterolemia (FH)

Several important updates for FH management:

• Standard risk calculators should not be used in HeFH (COR 3 — these patients are always at elevated risk regardless of what the calculator says)
• Genetic testing for pathogenic FH variants is reasonable in adults with LDL-C ≥190 mg/dL without secondary causes (COR 2a)
• For HeFH without ASCVD: goal LDL-C <70 mg/dL; with ASCVD: goal <55 mg/dL
• Homozygous FH (HoFH): evinacumab added as an option when LDL-C remains ≥100 mg/dL on max therapy including PCSK9 mAbs (COR 2b)

CKD Stage 3 or Higher with ASCVD

New COR 1 recommendation: these patients should receive high-intensity statin therapy ± ezetimibe ± PCSK9 mAb to achieve ≥50% LDL-C reduction with a goal of <55 mg/dL. This aligns CKD+ASCVD patients with the very high-risk secondary prevention tier.

People Living with HIV

A brand-new COR 1 recommendation: adults aged 40–75 living with HIV on stable antiretroviral therapy should receive statin therapy to reduce first ASCVD event risk and slow coronary atherosclerosis progression. This is a particularly important addition given the cardiovascular risk profile of this population.

Cancer Survivors

New COR 1: adult cancer survivors with life expectancy ≥2 years who otherwise qualify for lipid-lowering therapy should be treated the same as patients without cancer history. Don't withhold guideline-indicated therapy due to oncologic history alone.

07 — TriglyceridesUpdated Guidance Including New Therapies

Persistently elevated triglycerides deserve more attention under the 2026 framework. Key updates:

TG Management Highlights

TG 150–999 mg/dL with ASCVD: If LDL-C and non-HDL-C are above goal, intensify LDL-C lowering therapy first (COR 1).

TG ≥500 mg/dL: Refer to a registered dietitian nutritionist (RDN) for pancreatitis risk reduction.

TG 150–999 mg/dL + CKM syndrome features: RDN referral is also recommended.

Familial chylomicronemia syndrome (TG ≥1000 mg/dL): Olezarsen (an apoC3 inhibitor) is now COR 1 — the first guideline endorsement of this novel mechanism for pancreatitis prevention.

For adults 40–75 without ASCVD or diabetes but with persistently elevated TG (150–499 mg/dL), the guideline now recommends using PREVENT equations to estimate ASCVD risk and have a benefit-risk discussion about statin therapy — a new, proactive approach to this often-undertreated group.

08 — What's OutDietary Supplements — A Clear "No"

🚫 COR 3 — Do Not Recommend

For the first time, the guidelines include a Class III recommendation against dietary supplements for lowering LDL-C or triglycerides. This includes fish oil (for LDL/TG in non-pancreatitis settings), red yeast rice, berberine, plant sterols marketed as supplements, and other nutraceuticals. The evidence for meaningful cardiovascular benefit is limited and inconsistent. When patients ask about supplements, you now have guideline-level support for redirecting that conversation toward proven therapies and lifestyle changes.

Lower longer, start earlier, and treat to goal — the 2026 guidelines make it clear that cumulative lipoprotein exposure over a lifetime is what drives atherosclerosis, and NPs are on the front lines of changing that trajectory.

09 — For Your Practice10 High-Yield Takeaways to Implement Now

1

Order an Lp(a) on every adult — once

This is now a Class I recommendation. Add it to your next comprehensive lipid panel for any patient who hasn't had one. It's a one-time test with lifelong relevance.

2

Switch your risk calculator to PREVENT-ASCVD

The PCE is no longer the recommended tool. Bookmark the ACC PREVENT calculator and use it for every primary prevention conversation.

3

Know your patients' non-HDL-C goals

Non-HDL-C targets are now paired with every LDL-C goal. Non-HDL-C = total cholesterol − HDL-C; goals are 30 mg/dL higher than the corresponding LDL-C goal at each tier.

4

Ask about adverse pregnancy outcomes in all women

Preeclampsia, gestational diabetes, preterm delivery, and early menopause are now formal risk enhancers. Add these to your cardiovascular history intake questions.

5

Don't stop at statin intolerance — use bempedoic acid

Bempedoic acid has an expanded role in 2026, including as an add-on for very high-risk secondary prevention patients. It's a valuable oral option when statins aren't tolerated.

6

Treat your cancer survivors to the same LDL targets

If a cancer survivor with prior MI needs a high-intensity statin and their oncologist hasn't initiated one, that's a gap you can close in primary care.

7

Consider inclisiran for PCSK9-intolerant or access-challenged patients

Twice-yearly injection given in-office removes the adherence barrier of self-injection. It's now guideline-endorsed for very high-risk patients who can't access or tolerate the mAbs.

8

Start statins in your HIV-positive patients 40–75

This is now a Class I recommendation. Review your HIV-positive panel and assess who is and isn't on statin therapy — drug interactions with antiretrovirals matter, but pravastatin and rosuvastatin are generally safer choices.

9

Don't recommend dietary supplements for cholesterol

The guideline explicitly says no (Class III). Armed with this, you can redirect patients toward dietary patterns (Mediterranean, DASH, plant-forward) and proven pharmacotherapy.

10

Use incidental CAC findings on any CT — they count now

If a chest CT PE protocol mentions coronary calcification, that's clinically actionable information for lipid management. Review those radiology reports actively.

Final ThoughtsFrom One NP to Another

The 2026 dyslipidemia guidelines are the most comprehensive, practically actionable cholesterol guidelines we've had in years. They give us clearer targets, better risk tools, and more validated therapies — including several that are genuinely new to this iteration.

What stands out most to me is the underlying philosophy: treat earlier, treat to goal, and individualize based on the whole patient — including their reproductive history, comorbidities, imaging, and genetic context. The days of "start a statin and recheck in a year" without a specific target in mind are over.

For those of us in primary care and telehealth, these guidelines validate what many of us have already been doing intuitively — and give us the evidence-based language to advocate for more aggressive therapy when our patients need it.

📄 Full Guideline Reference

Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. DOI: 10.1016/j.jacc.2025.11.016. Available at acc.org and professional.heart.org.